Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Small Bone Innovations raises $108 million to launch STAR ankle: Orthopedic firm raises $108 million in a "Series D" private placement of preferred stock to help support the ongoing U.S. launch of its STAR total ankle replacement system. STAR became the first motion-preserving, mobile-bearing ankle replacement device available in the United States following PMA approval May 27 (1"The Gray Sheet" June 1, 2009). Announced June 30, the "Series D" financing closed in April; it follows a $36 million "Series C" funding round in 2008. Aside from supporting the STAR launch, proceeds from the offerings helped to complete the 2008 acquisition of the STAR technology from German firm Waldemar Link, as well as to retire a $20 million credit facility, according to the company

You may also be interested in...

STAR Becomes First Mobile-Bearing Ankle Approved In U.S.

Small Bone Innovations (SBi) hopes its STAR total ankle replacement system will be the catalyst for a shift in ankle procedures away from the fusion surgery standard toward a market dominated by joint replacement. But the barriers in the still-limited ankle replacement space are not trivial

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts